DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

Rhea-AI Summary

DBV Technologies (DBVT) will announce its third quarter 2022 financial results on November 3, 2022, at 5:00 p.m. ET via a conference call and live audio webcast. Investors can access the call using specific teleconferencing numbers. DBV is focused on developing Viaskin™, an innovative technology for epicutaneous immunotherapy aimed at treating food allergies, particularly through their ongoing clinical trials for Viaskin Peanut. A replay of the event will be available on the company's website.

Positive

• Ongoing clinical trials for Viaskin Peanut, showing progress in food allergy treatment.

Negative

• None.

Montrouge, France, October 31, 2022

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, at 5:00 p.m. ET to report third quarter 2022 financial results and provide a corporate update.

This call is accessible via the below teleconferencing numbers, followed by the reference ID: 94309191#.

• United States: 866 374 5140                                                
• Canada: 866 455 3403
• United Kingdom: 808 238 9813                                                
• France: 805 102 712

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com

Viaskin and EPIT are trademarks of DBV Technologies.

 

Attachment

• PDF Version

FAQ

What is the date for DBV Technologies' Q3 2022 earnings report?

DBV Technologies will report its Q3 2022 financial results on November 3, 2022.

How can I access DBV Technologies' Q3 2022 conference call?

The conference call can be accessed via specific teleconferencing numbers provided in the press release.

What is Viaskin and its significance for DBV Technologies?

Viaskin is DBV Technologies' proprietary platform for epicutaneous immunotherapy, aimed at treating food allergies.

Where can I find the webcast of the DBV Technologies earnings call?

The live webcast will be available in the Investors & Media section of DBV Technologies' website.